

बैंक ऑफ महाराष्ट्र
Bank of Maharashtra
कोलकाता का शाखा
कोलकाता

प्रधान कार्यालय: 'लोकमंगल', 1501, शिवाजीनगर, पुणे - 411005
फोन: 020 25511360 ईमेल: investor_services@mahabank.co.in
वेबसाइट: www.bankofmaharashtra.in

केंद्र सरकार के अलावा एक शेयरधारक निदेशक के चुनाव के लिए बैंक की वार्षिक साधारण बैठक (एजीएम)

बैंक उम्मीदवारों की सूची

उपरोक्त विषय पर दिनांक 14 मई, 2025 के समाचारपत्र प्रकाशनों और दिनांक 07 जून, 2025 के नोटिस (8 जून, 2025 को प्रकाशित) के अंतर्गत केंद्र सरकार के अलावा अन्य शेयरधारकों में से बैंक के एक शेयरधारक निदेशक के चुनाव के लिए बैंक की 22वीं वार्षिक साधारण बैठक आयोजित करने की सूचना दी गई है, तत्पश्चात बैंक को निम्नलिखित उम्मीदवारों से नामांकन प्राप्त हुए हैं, जिन्हें बैंक के निदेशक मंडल द्वारा बैंक और 'उपरोक्त तथा योग्य' पाया गया है।

क्र. सं.	उम्मीदवारों का नाम और पता	जन्मतिथि/ आयु (वर्ष)	शैक्षिक योग्यता	विशेष ज्ञान / अनुभव
1.	श्री. मृत्युंजय महापात्रा, डी 1501, साई साक्षात, सेक्टर 6, खारखर, नवी मुंबई 410210	03.05.1960 65 वर्ष	एम.एससी. (भौतिकी), प्रबंधन में डिप्लोमा, भारतीय बैंकर्स संस्थान के फेलो	लेखा, बैंकिंग, अर्थशास्त्र और वित्त
2.	श्री. अतुल जैन, 301, जॉय सॉलिटोर, एन एस रोड नंबर 5 जेवोपीडी स्कॉम, विले पार्ले पश्चिम, मुंबई 400056.	26.08.1962 62 वर्ष	वाणिज्य स्नातक (ऑनर्स), एफ.सी.ए., इन्स्टीट्यूट प्रोफेशनल	बैंकिंग, वित्त, विधि, लघु उद्योग, खुदरा बैंकिंग
3.	श्री. प्रसेनजीत श्रीकृष्ण फडणवीस, 31/34, रजनीनंदा हाउसिंग सोसायटी, तुलसीबागवाले कॉलोनी, सहकारनगर नंबर 2, पुणे - 411009	06.05.1973 52 वर्ष	कंप्यूटर विज्ञान में स्नातक, एल.एल.बी, साइबर कानून में डिप्लोमा	सूचना प्रौद्योगिकी, साइबर कानून, विधि
4.	श्री. आलोक जैन, एस-147, स्कूल ब्लॉक, शकरपुर, दिल्ली 110092	18.10.1970 54 वर्ष	वाणिज्य स्नातक, चार्टर्ड अकाउंटेंट, एसएमी प्रमाण	लेखा परीक्षा, कराधान, वित्तीय सलाहकार, म्यूचुअल, बैंकिंग, एनबीएफसी और परामर्श सेवाएं

यदि एक रिक्ति के लिए बैंक उम्मीदवारों वाले चार उम्मीदवार हैं, अतः बैंक ऑफ महाराष्ट्र (शेयर और बैंक) विनियम, 2004 के विनियम 66 के अनुसार में, 30 जून, 2025 को वीसी/ओपीएम के माध्यम से होने वाली बैंक की 22 वीं वार्षिक साधारण बैठक में चुनाव आयोजित किए जाएंगे। एजीएम के साथ ही चुनाव पर रिमोट वोटिंग मुख्यालय, 26 जून 2025 को सुबह 9:00 बजे से रविवार, 29 जून 2025 को शाम 5:00 बजे तक आयोजित की जाएगी।

बहुमत प्राप्त करने वाले उम्मीदवार को बैंक के शेयरधारक निदेशक के रूप में निर्वाचित घोषित किया जाएगा।

दिनांक: 19.06.2025

स्थान: पुणे

बैंक ऑफ महाराष्ट्र के लिए
विशाल सेठिया
कंपनी सचिव

Before the Learned Sole Arbitrator
Mr. Arnab Chakravorty, Advocate
Ref: A.P. (COM) NO. 831 OF 2024
Classic Leasing and Finance Ltd.

... Petitioner

... Respondents

Chhappan Bhog & Ors.
To:
1. CHAPPAN BHOG, Sweet Shop, through its
partners namely Mr. Raghav Saraf and
Rashmi Saraf, shop address at Nilambar,
Shop No. SR 5A, Ground Floor, 2AB,
Shakespeare Sarani, Kolkata-700017.
(Respondent No. 1)
2. RAGHAV SARAF, Son of Late Alok Saraf,
partner of Chhappan Bhog, residing at 128,
Sarat Bose Road, 3rd Floor, Kolkata-700029
(opp. Mangal-Hospital). (Respondent No. 2)
3. RASHMI SARAF, wife of Late Alok Saraf,
partner of Chhappan Bhog, residing at 128,
Sarat Bose Road, 3rd Floor, Kolkata-700029
(opp. Mangal-Hospital). (Respondent No. 3)

GREETINGS:
In terms of the directions passed by the
Learned Arbitral Tribunal vide minutes dated
21st May 2025 in the arbitral reference in the
above mentioned matter, Learned Arbitral
Tribunal fix the next date of the Arbitral sitting is
fixed on 7th July 2025 at 7:30 pm virtually. The
above mentioned respondents should contact
the Claimants Advocate on record as details
given below:
Mullick & Co. Advocates,
1B Old Post Office Street, Emerald House,
Room no. 22, 3rd Floor,
Kolkata-700026
Contact: 9073196826

"IMPORTANT"

Whilst care is taken prior to
acceptance of advertising
copy, it is not possible to verify
its contents. The Indian
Express (P) Limited cannot
be held responsible for such
contents, nor for any loss or
damage incurred as a result of
transactions with companies,
associations or individuals
advertising in its newspapers
or Publications. We therefore
recommend that readers
make necessary inquiries
before sending any monies
or entering into any
agreements with advertisers
or otherwise acting in any
manner whatsoever.



Moneywise. Be wise.

SMC GLOBAL SECURITIES LIMITED

PRESS RELEASE

SMC Global Securities Limited Clarifies Interest Payment Structure and Recent Price Movement of its Non-Convertible Debentures (NCDs)

SMC Global Securities Limited ("the Company") has noted unusual trades occurring at a very less/negative yields in its recently listed Non-Convertible Debentures (NCDs) with ISINs - INE103C07124 (Series VIII - 10% SMC/III2027) and INE103C07116 (Series X - 10.25% SMCX2028). The Company confirms that there is no undisclosed material information driving this volatility and reiterates key terms, including the cumulative interest payment structure.

Key Features of these series of NCDs (ISINs INE103C07124 & INE103C07116):

ISIN	Series	Tenor	Interest Type	Interest Payment Frequency	Redemption/ Maturity Value (₹)	Effective Yield (p.a.)	Maturity Date
INE103C07124	Series VIII - 10% SMC/III2027	24 months	Cumulative	On Maturity (April 24, 2027)	₹1,210	10.00%	April 24, 2027
INE103C07116	Series X - 10.25% SMCX2028	36 months	Cumulative	On Maturity (April 24, 2028)	₹1,340.10	10.25%	April 24, 2028

Clarification on Interest Payments:

Both NCD series are cumulative, meaning Interest is compounded and paid only upon maturity along with the Principal. There are no interim interest payments; investors will receive the full Redemption Value (Principal + Accrued Interest) per NCD on the specified maturity dates i.e. ₹1,210 in case of Series VIII (ISIN INE103C07124) and ₹1,340.10 in case of Series X (ISIN INE103C07116).

Investor Advisory:

The Company urges investors to:

- Refer Chapter- The Issue Structure on Page 232 of the Prospectus dated March 19, 2025 for complete terms of the NCDs.
- Base their investment decisions on the fixed redemption value and effective yield.
- Consult financial advisors if uncertain about the cumulative interest mechanism.

For details, visit <https://www.smcindiaonline.com/wp-content/uploads/2024/07/Prospectus-2025-1.pdf>

Sd/-
Suman Kumar

E.V.P. (Corporate Affairs & Legal)

SMC Global Securities Limited

Email: sumankumar@smcindiaonline.com

Date: June 19, 2025

Disclaimer: This announcement is informational. Market prices do not impact the fixed maturity payout. Investors should assess risks independently.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Aptus Pharma Ltd.

Connecting... Life

APTUS PHARMA LIMITED

CIN: U24230GJ2010PLC061957

Our Company was originally incorporated as "Aptus Pharma Private Limited", as a private limited company under the Companies Act, 1956, with the Registrar of Companies ("ROC"), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of our Company was changed to "Aptus Pharma Limited" and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. For further details please refer to chapter titled "History and Certain Corporate Matters" beginning on Page No. 161 of this Draft Red Herring Prospectus.

Registered Office: Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427.

Corporate Office: SHREE Building 1st Floor Opp Satyasai Heart Hospital, Narayan Nagar Kalawad Road, Rajkot Saur Umi Area Rajkot, Gujarat, 360005

Telephone: +91 76004 27827; **Email:** info@aptuspharma.com; **Website:** www.aptus-pharma.com;

Contact Person: Mohini Hardikbhai Gandhi, Company Secretary and Compliance Officer.

OUR PROMOTERS: TEJASH MAHESHCHANDRA HATHI, CHATRBHUJ VALLABHBHAI BUTANI, KAPILBHAI HASMUKHBHAI CHANDARANA, GHANSHYAM VINUBHAI PANSURIYA, MILLY CHETAN LALSETA, RIDDHISH NATWARLAL TANNA, GAURANG RAMESHCHANDRA THAKKER, KRIPALIBEN MAYANK THAKKER AND KUNJAL PIYUSHBHAI UNADKAT

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED."

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 20,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF APTUS PHARMA LIMITED (THE "COMPANY" OR "APTUS" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [-] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [-] ("THE ISSUE"), OF WHICH [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [-] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE AGGREGATING TO ₹ [-] WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF [-] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [-] PER EQUITY SHARE AGGREGATING TO ₹ [-] LACS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [-] % AND [-] % RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [-] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [-] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND [-] (A WIDELY CIRCULATED GUJARATI NATIONAL DAILY NEWSPAPER) WHERE OUR REGISTERED OFFICE IS LOCATED, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE SME") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, recorded in writing to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be reported to the revised Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI (ICDR) Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders, out of which (a) one third of such portion was reserved for applicants with application size of more than 2 lots and up to such lots equivalent to not more than 10,00,000 and (b) two-third of such portion was reserved for applicants with application size of more than 10,00,000 provided that the unsubscribed portion in either of such sub-categories could have been allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI (ICDR) Regulations, subject to valid Bids being received at or above the Issue Price. Further, Equity Shares capital will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RiBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For further details please refer the section titled "Issue Procedure" beginning on page no. 298 of this Draft Red Herring Prospectus. Provided further that for the purpose of public issue by an issuer to be listed/issued on SME exchange made in accordance with Chapter IX of these regulations, the words "Retail Individual Investors" shall be read as words "Individual Investors who applies for minimum application size" A copy will be filed with the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS [-] TIMES OF THE FACE VALUE

This public announcement is being made in compliance with and in accordance with SEBI press release no. PR No. 36/2024 dated December 18, 2024 (208) SEBI Board meeting on "Review of SME framework under SEBI (ICDR) Regulations, 2018, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies) to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and has filed the Draft Red Herring Prospectus dated June 18, 2025 which has been filed with the SME Platform of BSE Limited ("BSE SME" or "BSE"). In relation to above, the Draft Red Herring Prospectus filed with BSE shall be made available to the public for comments, if any, for a period of at least 21 days, from the date mentioned below by hosting it on the respective websites of the Stock Exchange i.e. BSE at www.bseindia.com, website of the Company at www.punjabiangithi.in and the website of the Book Running Lead Manager to the Issue at www.corporatemakers.in. Our Company hereby invites the members of the public to give comments on the Draft Red Herring Prospectus filed with BSE with respect to disclosures made in the Draft Red Herring Prospectus. The members of the public are requested to send a copy of their comments to BSE and to the Company Secretary and Compliance Officer (compliance@punjabiangithi.in) of our Company and for the Book Running Lead Manager of the issue at their respective addresses mentioned herein below in relation to the issue on or before 5:00 PM, on the 21st day i.e. 21 days from the date of filing of 'Issue Document with SME Platform of BSE Limited ("BSE SME").

Investment in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this issue. For taking an investment decision, investors must rely on their own examination of the issuer and the issue; including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the statement of "Risk Factors" given on page 30 of the Draft Red Herring Prospectus. Any decision to invest in the Equity Shares described in the Draft Red Herring Prospectus may only be made after the Red Herring Prospectus has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus.

The Equity Shares, when offered, through the Red Herring Prospectus, and proposed to be listed on the SME Platform of BSE Limited ("BSE SME" or "BSE"). For details of the main objects of our Company as contained in its Memorandum of Association, see "History and Corporate Structure" on page 192 of the Draft Red Herring Prospectus.

The liability of the members of our Company is limited, For details of the share capital, capital structure of our Company, the names of the signatories for the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 72 of the Draft Red Herring Prospectus.

CORPORATE MAKERS CAPITAL LIMITED	BIGSHARE SERVICES PRIVATE LIMITED
611, 6th Floor, Pragati Tower, Rajendra Place, New Delhi- 110008 Telephone: 011 41411600 Email: info@corporatemakers.in ; Website: www.corporatemakers.in Investor Grievance Email: compliance@corporatemakers.in ; Contact Person: Mr. Rohit Pareek SEBI Registration Number: INM000013095 CIN: U65100DL1994PLC063880	S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra -400 093 Telephone: 022-62638200 Email ID: ipo@bigshareonline.com ; Investor grievance email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Babu Rappheal C SEBI Registration Number: INR000001385 CIN: U99999MH1994PTC076534

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed in the Draft red herring Prospectus

For **Vegorama Punjabi Angithi Limited**
On behalf of the Board of Directors

Sd/-
Karuna Sharma
Company Secretary and Compliance Officer

Vegorama Punjabi Angithi Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus with BSE on June 18, 2025, The Draft Red Herring Prospectus shall be available on the website of the BSE at www.bseindia.com and is available on website of the Company i.e. www.punjabiangithi.in, website of the Lead Manager to the issue, Corporate Makers Capital Limited at www.corporatemakers.in. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 30 of the Draft Red Herring Prospectus and the details set out in the Prospectus, when filed. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States under the U.S. Securities Act of 1933 or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, the securities described in this announcement are not being offered or sold in the United States.

LEAD MANAGER OF THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 INTERACTIVE FINANCIAL SERVICES LIMITED Address: Office No. 508, Fifth Floor, Priviera, Nehru Nagar, Ahmedabad - 380 015, Gujarat, India Tel No.: 079 4908 8019 (M) +91-9898005567 Web Site: www.ifinservices.in Email: mhd@ifinservices.in Investor Grievance Email: info@ifinservices.in Contact Person: Pradip Sandhir SEBI Reg. No.: INM000012856	 BIGSHARE SERVICES PRIVATE LIMITED CIN: U99999MH1994PTC076534 Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093 Telephone: 022-62638200 Email: ipo@bigshareonline.com Investor Grievance e-mail: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Babu Rappheal C SEBI registration number: INR000001385	Name: Mohini Hardik Gandhi Address: Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427 E-mail: info@aptuspharma.com Investor grievance id: complianceofficer@aptuspharma.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **APTUS PHARMA LIMITED**
On Behalf of the Board of Directors

Sd/-
Mohini Hardik Gandhi
Company Secretary and Compliance Officer

Disclaimer: APTUS PHARMA LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on June 18, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at <https://www.bsesme.com/PublicIssues/SMEIPODRHP.aspx>, offer and is available on the websites of the BRLM at www.ifinservices.in and also on the website of the Company www.aptus-pharma.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 26 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.